Savara Inc. Aktie
3,84 €
Deine Einschätzung
Savara Inc. Aktie
Was spricht für und gegen Savara Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Savara Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Savara Inc. | 1,05 % | 2,13 % | -16,16 % | 41,18 % | -11,11 % | 161,22 % | -60,34 % |
Rockwell Medical Inc. | -2,03 % | -3,33 % | 12,87 % | -53,74 % | -7,96 % | -80,41 % | -96,38 % |
Avid Bioservices Inc | - | -9,88 % | 1,39 % | -50,68 % | 19,67 % | -58,99 % | 113,17 % |
Gritstone Oncology Inc | -1,05 % | -7,23 % | -14,61 % | -64,13 % | -63,05 % | -91,16 % | - |
Kommentare
News
Savara to Present at the Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On May 14, 2024